175 related articles for article (PubMed ID: 20724078)
1. Luteinising hormone releasing hormone agonists (LH-RHa) in premenopausal early breast cancer patients: current role and future perspectives.
Del Mastro L; Levaggi A; Giraudi S; Pronzato P
Cancer Treat Rev; 2011 May; 37(3):208-11. PubMed ID: 20724078
[TBL] [Abstract][Full Text] [Related]
2. Luteinizing hormone-releasing hormone agonists in premenopausal hormone receptor-positive breast cancer.
Tan SH; Wolff AC
Clin Breast Cancer; 2007 Feb; 7(6):455-64. PubMed ID: 17386122
[TBL] [Abstract][Full Text] [Related]
3. New insights on the role of luteinizing hormone releasing hormone agonists in premenopausal early breast cancer patients.
Del Mastro L; Rossi G; Lambertini M; Poggio F; Pronzato P
Cancer Treat Rev; 2016 Jan; 42():18-23. PubMed ID: 26613834
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant therapy for premenopausal patients with early breast cancer.
Kurebayashi J
Curr Opin Obstet Gynecol; 2008 Feb; 20(1):51-4. PubMed ID: 18197006
[TBL] [Abstract][Full Text] [Related]
5. [Current status of adjuvant endocrine therapy for hormone responsive breast cancer].
Ikeda T; Jinno H; Masamura S; Matsui A; Tajima G; Hohjoh T; Tokura H; Mitsui Y; Asaga S; Muto T; Fujiwara K; Kitajima M
Gan To Kagaku Ryoho; 2001 Jul; 28(7):902-8. PubMed ID: 11478138
[TBL] [Abstract][Full Text] [Related]
6. [The use of GnRH analogues in early and advanced breast carcinomas].
Ségura C; Avenin D; Gligorov J; Selle F; Estéso A; Beerblock K; Emile G; Do Huyen N; Lotz JP
Gynecol Obstet Fertil; 2005 Nov; 33(11):914-9. PubMed ID: 16246613
[TBL] [Abstract][Full Text] [Related]
7. Ovarian ablation as treatment for young women with breast cancer.
Davidson NE
J Natl Cancer Inst Monogr; 1994; (16):95-9. PubMed ID: 7528032
[TBL] [Abstract][Full Text] [Related]
8. Use of goserelin in the treatment of breast cancer.
Rody A; Loibl S; von Minckwitz G; Kaufmann M
Expert Rev Anticancer Ther; 2005 Aug; 5(4):591-604. PubMed ID: 16111461
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma.
Recchia F; Saggio G; Amiconi G; Di Blasio A; Cesta A; Candeloro G; Rea S
Cancer; 2006 Feb; 106(3):514-23. PubMed ID: 16388519
[TBL] [Abstract][Full Text] [Related]
10. [A case of a premenopausal woman with advanced breast cancer treated with aromatization inhibition in combination with luteinizing hormone-releasing hormone agonist].
Hisamatsu K; Iwamori S; Minami K; Tanabe K; Ota K; Akiyama H
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1327-30. PubMed ID: 9279354
[TBL] [Abstract][Full Text] [Related]
11. Combined ovarian ablation and aromatase inhibition as first-line therapy for hormone receptor-positive metastatic breast cancer in premenopausal women: report of three cases.
El-Saghir NS; El-Hajj II; Makarem JA; Otrock ZK
Anticancer Drugs; 2006 Sep; 17(8):999-1002. PubMed ID: 16940812
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant endocrine treatment in premenopausal early breast cancer.
Orlando L; Fedele P; Cinefra M; Sponziello F; Calvani N; Chetrì MC; Rizzo P; D'Amico M; Schiavone P; Portaluri M; Criscuolo M; Burlizzi S; Cinieri S
Oncology; 2009; 77 Suppl 1():9-13. PubMed ID: 20130426
[TBL] [Abstract][Full Text] [Related]
13. [Hormone therapy in breast cancer: the end of tamoxifen?].
Delozier T
Bull Cancer; 2005 Feb; 92(2):142-50. PubMed ID: 15749643
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density among premenopausal women with early breast cancer in a randomized trial of adjuvant endocrine therapy.
Sverrisdóttir A; Fornander T; Jacobsson H; von Schoultz E; Rutqvist LE
J Clin Oncol; 2004 Sep; 22(18):3694-9. PubMed ID: 15365065
[TBL] [Abstract][Full Text] [Related]
15. Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study.
Celio L; Martinetti A; Ferrari L; Buzzoni R; Mariani L; Miceli R; Seregni E; Procopio G; Cassata A; Bombardieri E; Bajetta E
Anticancer Res; 1999; 19(3B):2261-8. PubMed ID: 10472341
[TBL] [Abstract][Full Text] [Related]
16. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.
; Cuzick J; Ambroisine L; Davidson N; Jakesz R; Kaufmann M; Regan M; Sainsbury R
Lancet; 2007 May; 369(9574):1711-23. PubMed ID: 17512856
[TBL] [Abstract][Full Text] [Related]
17. LH-RH agonists offer very good protection against the adverse gynaecological effects induced by tamoxifen.
Berlière M; Galant C; Marques G; Piette P; Duck L; Fellah L; Donnez J; Machiels JP
Eur J Cancer; 2004 Aug; 40(12):1855-61. PubMed ID: 15288287
[TBL] [Abstract][Full Text] [Related]
18. [Adjuvant endocrine therapy for breast cancer].
Iino Y; Takei H; Morishita Y
Gan To Kagaku Ryoho; 1995 Apr; 22 Suppl 1():81-7. PubMed ID: 7747997
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant therapy with GnRH agonists/tamoxifen in breast cancer should be a good council for patients with hormone receptor-positive tumours and wish to preserve fertility.
Franco JG; Oliveira JB; Petersen CG; Mauri AL; Baruffi R; Cavagna M
Med Hypotheses; 2012 Apr; 78(4):442-5. PubMed ID: 22284634
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant endocrine therapy in premenopausal women with breast cancer.
González Martín A; de la Cruz S; Márquez R
Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():43-7. PubMed ID: 20711666
[No Abstract] [Full Text] [Related]
[Next] [New Search]
